Base-case cost-effectiveness results for mild and moderate TBI patients treated with and without tranexamic acid in the UK and Pakistan
| Costs | LYs | QALYs | ICER (LY) | ICER (QALY) | CE threshold (per QALY) | Probability CE at threshold | |
| UK | |||||||
| Placebo | £55 110 | 16.87 | 12.10 | ||||
| Tranexamic acid | £55 869 | 17.12 | 12.28 | £3078 | £4288 | £20 000 | 99% |
| Pakistan | |||||||
| Placebo | US$92 | 14.97 | 10.83 | ||||
| Tranexamic acid | US$97 | 15.26 | 11.04 | US$17 | US$24 | US$158 | 98% |
CE, cost-effectiveness; ICER, incremental cost-effectiveness ratio; LY, life-years; QALY, quality-adjusted life-years; TBI, traumatic brain injury.